AKTS Stock Analysis: Aktis Oncology, Common stock | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.756m USD | 12M Return: 40.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 10.6M
Qual. Beats: 0
Rev. Trend: -50.3%
Warnings
Tailwinds
Seasonality 0.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Aktis Oncology, Inc. (NASDAQ: AKTS) is a clinical-stage biotechnology company based in Boston, Massachusetts, developing targeted radiopharmaceuticals for solid tumor cancers. Its lead candidate, [225Ac]Ac-AKY-1189, is a miniprotein radioconjugate currently in a Phase 1b trial targeting Nectin-4-expressing tumors such as urothelial, breast, lung, colorectal, and cervical cancers. A second candidate, [225Ac]Ac-AKY-2519, targets B7-H3 (CD276) expressing tumors including prostate and lung cancers.
The company holds license and collaboration agreements with Protein Innovation, TRIUMF Innovations, and Eli Lilly, and was formerly known as HotKnot Therapeutics before rebranding in April 2020. Aktis operates within the radiopharmaceuticals segment of oncology, a field that uses radioactive isotopes conjugated to tumor-targeting molecules to deliver localized radiation to cancer cells. The companys miniprotein-based platform is designed to improve tumor selectivity and reduce off-target toxicity compared to traditional small-molecule radioligands.
- Phase 1b AKY-1189 data readout in Nectin-4 solid tumors
- Eli Lilly collaboration milestones provide near-term funding
- Radiopharmaceutical competition intensifies from Novartis Pluvicto and Bayer Xofigo
| Net Income: -60.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.11 > 0.02 and ΔFCF/TA 7.42 > 1.0 |
| NWC/Revenue: 6.90k% < 20% (prev 923.0%; Δ 5.98k% < -1%) |
| CFO/TA -0.12 > 3% & CFO -69.8m > Net Income -60.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 19.49 > 1.5 & < 3 |
| Outstanding Shares: last quarter (55.3m) vs 12m ago -64.21% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 1.66% > 50% (prev 9.37%; Δ -7.71% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.89 (Total Current Assets 543.9m - Total Current Liabilities 27.9m) / Total Assets 576.8m |
| B: -0.30 (Retained Earnings -174.9m / Total Assets 576.8m) |
| C: -0.16 (EBIT TTM -73.9m / Avg Total Assets 451.5m) |
| D: 7.16 (Book Value of Equity 506.1m / Total Liabilities 70.7m) |
| Altman-Z'' = 11.30 = AAA |
| DSRI: 1.70 (Receivables 2.20m/5.29m, Revenue 7.48m/30.6m) |
| GMI: 0.14 (GM 13.90% / 100.0%) |
| AQI: 0.60 (AQ_t 0.01 / AQ_t-1 0.01) |
| SGI: 0.24 (Revenue 7.48m / 30.6m) |
| TATA: 0.02 (NI -60.5m - CFO -69.8m) / TA 576.8m) |
| Beneish M = -4.01 (Cap -4..+1) = AAA |
As of July 08, 2026, the stock is trading at USD 27.58 with a total of 486,533 shares traded. Over the past week, the price has changed by -8.40%, over one month by +45.39%, over three months by +64.95% and over the past year by +40.93%.
Current recommended Stop Loss: 23.60 (which is 14.4% or 1.5 ATR below the current price).
Aktis Oncology, Common stock has no consensus analysts rating.
P/S = 212.1073
P/B = 3.4688
Revenue TTM = 7.48m USD
EBIT TTM = -73.9m USD
EBITDA TTM = -71.6m USD
Long Term Debt = 10.1m USD (estimated: total debt 11.6m - short term 1.43m)
Short Term Debt = 1.43m USD (from shortTermDebt, last quarter)
Debt = 11.6m USD (from shortLongTermDebtTotal, last quarter) (leases 11.6m already included)
Net Debt = -506.1m USD (calculated: Debt 11.6m - CCE 517.7m)
Enterprise Value = 1.25b USD (1.76b + Debt 11.6m - CCE 517.7m)
Interest Coverage Ratio = unknown (Ebit TTM -73.9m / Interest Expense TTM 0.0)
EV/FCF = -20.17x (Enterprise Value 1.25b / FCF TTM -62.0m)
FCF Yield = -4.96% (FCF TTM -62.0m / Enterprise Value 1.25b)
FCF Margin = -828.6% (FCF TTM -62.0m / Revenue TTM 7.48m)
Net Margin = -809.2% (Net Income TTM -60.5m / Revenue TTM 7.48m)
Gross Margin = unknown ((Revenue TTM 7.48m - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 2.17 (Enterprise Value 1.25b / Total Assets 576.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 11.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -58.3m (EBIT -73.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 18.67 (Total Current Assets 543.9m / Total Current Liabilities 29.1m)
Debt / Equity = 0.02 (Debt 11.6m / totalStockholderEquity, last quarter 506.1m)
Debt / EBITDA = 7.07 (negative EBITDA) (Net Debt -506.1m / EBITDA -71.6m)
Debt / FCF = 8.17 (negative FCF - burning cash) (Net Debt -506.1m / FCF TTM -62.0m)
Total Stockholder Equity = 34.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -13.40% (Net Income -60.5m / Total Assets 576.8m)
RoE = -173.2% (Net Income TTM -60.5m / Total Stockholder Equity 34.9m)
RoCE = -163.8% (out of range, set to none) (EBIT -73.9m / Capital Employed (Equity 34.9m + L.T.Debt 10.1m))
RoIC = -10.61% (negative operating profit) (NOPAT -58.3m / Invested Capital 549.9m)
WACC = 13.45% (E(1.76b)/V(1.77b) * Re(13.54%) + D(11.6m)/V(1.77b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 13.54% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: -8.99 | Cagr: -8.91%
[DCF] Fair Price = unknown (Cash Flow -62.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.01 | # QB: 0
Revenue Correlation: -50.28 | Revenue CAGR: -20.59% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.44 | Chg30d=+7.92% | Revisions=-40% | Analysts=5
EPS next Quarter (2026-09-30): EPS=-0.47 | Chg30d=+6.62% | Revisions=-40% | Analysts=5
EPS current Year (2026-12-31): EPS=-1.60 | Chg30d=+1.35% | Revisions=-40% | GrowthEPS=+98.0% | GrowthRev=+62.8%
EPS next Year (2027-12-31): EPS=-1.94 | Chg30d=+10.83% | Revisions=-40% | GrowthEPS=-20.8% | GrowthRev=+9.2%
[Analyst] Revisions Ratio: -73% (up=0, down=8)